ArticleEuropean journal of medical research2025
Evaluation of the diagnostic performance of YiDiXie™ tests in urothelial carcinoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the diagnostic value of three YiDiXie tests in prostate cancer: an observational prospective single-center study.Scientific reports · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundComputed tomography (CT) is widely used to the diagnosis of upper urinary tract epithelial tumors, but the relatively inaccurate results may affect subsequent treatment. Cystoscopy is widely used for preoperative diagnosis of bladder tumors and postoperative review of urothelial carcinoma, but its invasiveness and corresponding complications are feared by patients. There is an urgent need to find a convenient, cost-effective and non-invasive diagnostic method to reduce the false-positive and false-negative rates of urinary tract CT, and to replace cystoscopy in the preoperative diagnosis of bladder tumors or postoperative monitoring the bladder for recurrent of urothelial carcinoma. The study aimed to evaluate the diagnostic value of YiDiXie™-30, YiDiXie™-32, and YiDiXie™-48 in urothelial cancer. MATERIALS AND
methods439 study subjects were finally included in this study (malignant group, n = 292, benign group, n = 90; relapse group, n = 22, relapse-free group, n = 35). The remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity, positive likelihood ratio, and negative likelihood ratio of YiDiXie™-30, YiDiXie™-32, and YiDiXie™-48. Receiver-operating characteristic curves' analyses were included in this study.
resultsThe sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of YiDiXie™-30 were 74.7%, 92.2%, 9.6, and 0.27, respectively. The sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of YiDiXie™-32 were 86.6%, 84.4%, 5.6, and 0.16, respectively. The sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were 96.2%, 65.6%, 2.8, and 0.06, respectively. Further studies revealed that YiDiXie™-30, YiDiXie™-32, and YiDiXie™-48 had similar results in patients with positive or negative urothelial CT. The negative likelihood ratios of YiDiXie™-30, YiDiXie™-32, and YiDiXie™-48 with ultrasound concurrently in the relapse and relapse-free groups were 0.05, 0.05, and 0. In the malignant and benign groups with diameters < 2.0 cm negative likelihood ratios of YiDiXie™-30.
conclusionYiDiXie™ tests showed considerable validity in the diagnosis of urothelial carcinoma with significantly different levels of sensitivity and specificity. They have significant diagnostic value in urothelial carcinoma, improving the diagnosis of upper urinary tract epithelial tumors and potentially providing an alternative to cystoscopy in combination with CT or ultrasound. Clinical study registration number ChiCTR2200066840.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.